
Faropenem, a novel oral penem antibiotic, is being developed to address the increasing resistance of S. pneumoniae strains to penicillin. It has broad-spectrum antibacterial activity and shows efficacy against respiratory pathogens. Faropenem has improved stability and decreased CNS effects due to its chiral tetrahydrofuran substituent. It resists hydrolysis and exhibits stable bactericidal activity in serum. In India, clinicians prescribe faropenem for ESBL-producing Enterobacteriaceae, leading to higher consumption than carbapenems. Studies have demonstrated its effectiveness in treating community-acquired pneumonia, with similar cure rates to amoxicillin. Faropenem has a favorable safety profile, making it a potential first-line treatment option for community-acquired infections in India.
Like
Save
Share